Krystal Biotech, Inc. (KRYS)
After hours:
| Previous Close | 160.23 |
| Open | 163.55 |
| Bid | 160.55 x 100 |
| Ask | 161.17 x 100 |
| Day's Range | 157.90 - 164.74 |
| 52 Week Range | 82.75 - 189.97 |
| Volume | |
| Avg. Volume | 386,077 |
| Market Cap | 4.594B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 423.95 |
| EPS (TTM) | 0.38 |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 188.50 |
ZacksWhy Krystal Biotech (KRYS) Might Surprise This Earnings Season
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlobeNewswireKrystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as foll
- GlobeNewswire
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 6, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the l
